Biologically active withanolides from Withania coagulans.

Area of Science:

• Natural Product Chemistry
• Pharmacology
• Cancer Research

Background:

• Withania coagulans is a plant with traditional medicinal uses.
• Cancer chemoprevention research focuses on identifying natural compounds that can prevent or delay cancer development.
• Nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) mediated nuclear factor-kappa B (NF-κB) signaling pathways are implicated in cancer progression.

Purpose of the Study:

• To isolate and characterize novel bioactive compounds from Withania coagulans with potential cancer chemopreventive properties.
• To evaluate the inhibitory effects of isolated compounds on nitric oxide production and TNF-α-induced NF-κB activation in relevant cellular models.

Main Methods:

• Bioassay-directed isolation and purification of crude Withania coagulans extract.
• Structure elucidation using spectroscopic techniques (1D/2D NMR, mass spectrometry, CD analysis) and X-ray diffraction.
• In vitro assays to measure inhibition of nitric oxide production in lipopolysaccharide-activated RAW 264.7 cells.
• In vitro assays to assess inhibition of TNF-α-induced NF-κB activation.

Main Results:

• Three new steroidal lactones, withacoagulin G, H, and I, were isolated, along with six known derivatives.
• Compounds 1-9 demonstrated inhibition of nitric oxide production, with IC(50) values ranging from 1.9 to 38.2 μM. Withacoagulin H (2) was the most potent (IC(50) 1.9 μM).
• All tested withanolides (1-9) inhibited TNF-α-induced NF-κB activation, with IC(50) values between 1.60 and 12.4 μM.

Conclusions:

• The study successfully identified novel steroidal lactones from Withania coagulans with significant anti-inflammatory and potential chemopreventive activities.
• The isolated compounds, particularly withacoagulin H, show promise as therapeutic agents targeting pathways involved in cancer development.
• Further investigation into the mechanisms and in vivo efficacy of these compounds is warranted.